By Nana O 
Immunotherapy has heralded a new era in cancer treatment, dramatically improving outcomes for patients with a variety of malignancies. However, its application to brain tumors, particularly gliomas, has been met with significant challenges. These aggressive tumors possess a remarkable ability to create an immunosuppressive microenvironment, effectively shielding themselves from the body’s natural defenses and rendering many immunotherapeutic strategies less potent. Now, groundbreaking research from a collaborative effort between the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute (DFCI) offers a critical insight into these immune-suppressing mechanisms, paving the way for potentially more effective immunotherapies for brain cancer patients.
The study, published in the prestigious journal Nature, delved into the intricate cellular landscape of gliomas, the most common and often deadliest form of primary brain cancer. Researchers meticulously analyzed nearly 200,000 individual immune cells, specifically focusing on myeloid cells, which are known players in immune regulation and can contribute to tumor evasion. Their comprehensive analysis revealed four distinct "gene expression programs"—coordinated patterns of gene activity—within these myeloid cells. These programs were found to either actively suppress the immune system or, conversely, promote immune activation. Crucially, the research also identified a concerning link between dexamethasone, a widely used steroid treatment for brain cancer patients, and one of these immunosuppressive programs. This finding suggests that a common supportive therapy might inadvertently be diminishing the effectiveness of immunotherapy.
Deciphering the Myeloid Cell Blueprint
The journey to these significant findings began with a fundamental question: why do immunotherapies, which have shown remarkable success against other cancers, struggle against brain tumors? Dr. Tyler Miller, co-first author on the study and a resident in clinical pathology at Massachusetts General Hospital at the time of the research, observed firsthand the limited success of various treatments for glioma patients. His desire to bridge the gap between the promise of immunotherapy and its challenges in the brain led him to focus on myeloid cells.
"As a pathology resident, I witnessed treatment after treatment fail in patients with gliomas," Dr. Miller stated. "I had seen the profound difference immunotherapy made for other cancers, and I was driven to understand how we could improve its application for brain cancer."
Myeloid cells constitute a substantial portion, sometimes up to half, of the cellular makeup within many brain tumors. Their inherent capacity to dampen immune responses presents a formidable barrier to the immune system’s ability to target and eliminate cancerous cells. To unravel the complex behavior of these cells, Miller and his colleagues employed single-cell RNA sequencing, a sophisticated technique that allows for the examination of gene expression in individual cells. This allowed them to scrutinize nearly 200,000 cells sourced from 85 distinct glioma tumors.
The research team utilized a novel analytical approach developed at the Broad Institute in 2019 called consensus non-negative matrix factorization (cNMF). This method diverges from traditional single-cell analysis, which typically clusters cells based solely on their identity markers. Instead, cNMF can independently define cells by both their identity and their functional activity. This independent characterization proved vital in identifying the nuanced roles of myeloid cells.
"This study provides us with the data we need to create myeloid-targeting strategies to modulate these programs and make immunotherapies more effective for brain tumor patients," Dr. Miller emphasized.
The application of cNMF led to the identification of the four key gene expression programs. Two of these programs were characterized by inflammatory activity, indicating an immune system that was potentially activated and engaged in an attempt to combat the tumor. The other two programs, predominantly observed in advanced tumors, were found to be immunosuppressive. These programs effectively orchestrated a shutdown of immune responses, significantly hindering the body’s ability to fight the cancer.
Dexamethasone’s Double-Edged Sword: New Insights into Treatment Interactions
One of the most striking discoveries of the study pertained to the immunosuppressive programs and their correlation with dexamethasone treatment. Dexamethasone, a corticosteroid, is frequently administered to brain cancer patients to manage cerebral edema, or brain swelling, which can occur with tumor growth. This medication is often given early in the treatment course, sometimes before immunotherapy is initiated.
While the immunosuppressive properties of dexamethasone were well-established, previous understanding primarily focused on its effects on T cells, a different type of immune cell critical for adaptive immunity. However, the new findings from the Broad Institute and DFCI research team suggest that dexamethasone exerts a potent influence on myeloid cells as well, driving one of the identified immunosuppressive programs. This revelation carries significant implications for how and when this common steroid should be prescribed, particularly in the context of immunotherapy.
"These gene signatures provide a roadmap that the field can use to study myeloid cells and how they impact the way brain tumors respond to therapy," stated Dr. Bradley Bernstein, an institute member at the Broad and chair of the cancer biology department at DFCI, who served as the study’s senior author.
The researchers’ analysis indicated that patients treated with dexamethasone exhibited heightened activity within one of the immunosuppressive myeloid cell programs. This observation raises concerns that the drug, while beneficial for symptom management, may be actively undermining the potential effectiveness of immunotherapies by dampening the immune response. This suggests a critical need for a more judicious use of dexamethasone in patients slated for or undergoing immunotherapy.
To further investigate this interaction, the team created three-dimensional cell cultures, known as organoids, from tumor samples of glioma patients. These organoids were then treated with dexamethasone. The results were compelling: myeloid cells within the organoids continued to express the immunosuppressive programs even after the drug was removed. This finding suggests that the steroid’s impact on immunotherapy response could be long-lasting, potentially affecting efficacy even if administered for a limited duration.
"We hope this will spur additional studies to identify ways to tackle edema [brain swelling] using different drugs and also to think about how we design clinical trials based on those results," Dr. Miller commented, highlighting the potential for improved patient management strategies.
Beyond dexamethasone, the organoid experiments also shed light on other factors that can drive immunosuppression within the tumor microenvironment. The researchers found that cell signaling molecules, including the inflammatory protein IL-1β and the growth factor TGF-β, played a role in promoting the expression of another immunosuppressive program in the tumors. This points to a complex interplay of factors that contribute to the tumor’s ability to evade immune detection.
Future Directions and Broader Implications
The implications of this research extend beyond a deeper understanding of brain tumor biology. The identification of these four distinct gene expression programs in myeloid cells provides a concrete target for the development of novel therapeutic strategies. By precisely modulating these programs, scientists could potentially enhance the immune system’s ability to recognize and attack brain tumors, thereby improving patient responses to immunotherapy.
"Scientists could one day manipulate the four programs with drugs to make immunotherapies more effective," Dr. Miller explained. "In the meantime, I hope that our approach highlights the importance of considering myeloid cells and will inspire other groups to study their roles in other tumors and patient populations."
The collaborative effort, which also included co-first authors Dr. Chadi El Farran, a postdoctoral researcher in Dr. Bernstein’s lab, and Dr. Charles Couturier, a postdoctoral researcher in Dr. Alex Shalek’s lab at the Broad and MIT, represents a significant leap forward in the fight against brain cancer. The meticulous single-cell analysis, coupled with the innovative application of cNMF, has provided an unprecedented level of detail into the immune landscape of gliomas.
The findings are likely to prompt a re-evaluation of current treatment protocols, particularly the use of dexamethasone in conjunction with immunotherapy. Future research will undoubtedly focus on developing targeted therapies that can counteract the immunosuppressive programs identified, potentially through agents that inhibit specific signaling pathways or activate immune-promoting functions within myeloid cells. Furthermore, the study’s emphasis on myeloid cells could encourage similar in-depth analyses in other cancer types where immunotherapy efficacy is suboptimal.
The research team’s commitment to translating these fundamental discoveries into clinical applications underscores the urgent need for improved treatments for brain cancer patients. By deciphering the intricate mechanisms that allow gliomas to evade immune surveillance, this work offers a beacon of hope for developing more potent and personalized immunotherapies that can finally overcome the formidable defenses of brain tumors. The roadmap provided by this study is poised to guide future investigations and, ultimately, improve the lives of those battling this devastating disease.